Exelixis (EXEL)

Add to Watchlists
Create an Alert
3.29 -0.03  -0.90% NASDAQ Apr 17, 8:00PM BATS Real time Currency in USD
View Full Chart
EXEL Price Chart
View All Events

EXEL Events

Date Type Description
Feb 20 Misc Exelixis, Inc. Q4 2013 Earning Conference Call
Feb 20 Earnings Exelixis, Inc. Q4 2013 Earning Result. Estimate: -0.38.
Nov 12 Misc Exelixis Announces Webcast of November 12 Presentation at the Credit Suisse 2013 Healthcare Conference
Oct 30 Misc Exelixis Announces October 30th Webcast of Third Quarter 2013 Financial Results Conference Call
Oct 30 Earnings Third Quarter 2013 Financial Results. Estimate: -0.38.
Aug 06 Misc Exelixis Announces August 6th Webcast of Second Quarter 2013 Financial Results Conference Call
Aug 06 Earnings Q2 2013 Exelixis, Inc. Earnings. Estimate: -0.29.
May 22 Misc AGM Event for Exelixis Inc
May 07 Misc Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call
May 07 Earnings Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results. Estimate: -0.26.
View All Performance Charts

EXEL Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Exelixis is down 32.02% over the last year vs S&P 500 Total Return up 20.96%, Regeneron Pharmaceuticals up 39.26%, and Cyclacel Pharmaceuticals down 34.40%.

Get Quote for

PDF Report for EXEL

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download EXEL Pro Report PDF

Portfolio Strategies Featuring EXEL

Did Exelixis make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

EXEL Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Research and Development in Biotechnology
  • NAICS Code: 541711
  • NAICS Industry: Scientific Research and Development Services
  • NAICS Industry Code: 5417
  • NAICS Sector: Professional, Scientific, and Technical Services
  • NAICS Sector Code: 54

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. The company is focusing its proprietary resources and development efforts exclusively on Cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes Cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. The company has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. It was founded on November 15, 1994 by Stelios B. Papadopoulos and Corey S. Goodman and is headquartered in South San Francisco, California.

Recent Quotes

Symbol Price Chg Chg % Market Cap
EXEL 3.29 -0.03 -0.90% 638.90M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership


{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.